Number of the records: 1
A Phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim in patients receiving first-line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for locally advance or metastatic colorectal cancer: final results of the pegfilgrastim and anti-VEGF evaluation study (PAVES)
Title A Phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim in patients receiving first-line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for locally advance or metastatic colorectal cancer: final results of the pegfilgrastim and anti-VEGF evaluation study (PAVES) article
Number of the records: 1